11 Best Drug Stocks to Buy According to Hedge Funds
Health and Human Services Secretary Robert F. Kennedy Jr.
Sanofi Aventis (SNY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 13,566,329 | $752,388,622 | +9% | 0.33% |
| 2. | Millennium Management Israel Englander | 1,082,793 | $60,051,700 | +267% | 0.03% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 846,415 | $46,942,176 | +203% | 0.04% |
| 4. | VGI Partners Robert M. P. Luciano | 765,366 | $42,447,198 | +6% | 4.35% |
| 5. | Armistice Capital Steven Boyd | 524,000 | $29,061,040 | -59% | 0.44% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 73,193,057 | $4,059,286,941 | 2.31% | |
| 2. | 11,859,545 | $657,730,379 | 0.12% | |
| 3. | 10,407,790 | $577,216,022 | 0.05% | |
| 4. | 8,323,947 | $461,646,101 | 0.07% | |
| 5. | 8,011,004 | $444,290,476 | 0.03% |
News See All
Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success
Sanofi (NASDAQ:SNY)’s shares fell 5% this week, even as the company announced positive results from its AERIFY-1 trial with Regeneron Pharmaceuticals, marking a significant advance in COPD treatment...
Stifel Maintains Buy Rating on Nurix (NRIX) Stock
On June 3, Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a price target of $35.
Morgan Stanley Resumes Sanofi (SNY) Coverage, Assigns Equal Weight Rating
On June 2, Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (NASDAQ:SNY), assigning an Equal Weight rating and setting a $56 price target.
Regeneron (REGN) Downgraded at RBC Capital, Price Target Cut Sharply
On May 30, RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc.
Sanofi (SNY)'s MenQuadfi Becomes First MenACWY Vaccine Approved for Ages 6 Weeks and Up
The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old.
Sanofi Set to Acquire Vigil Neuroscience in $470 Million Deal
Sanofi (NASDAQ:SNY) has announced a deal to acquire Vigil Neuroscience, a clinical-stage biotech company, for around $470 million, aiming to strengthen its research pipeline with a potential new Alzheimer...
Sanofi (SNY): A Bull Case Theory
We came across a bullish thesis on Sanofi (SNY) on Substack by Business Model Mastery. In this article, we will summarize the bulls’ thesis on SNY.
Sanofi (NASDAQ:SNY) Q1 2025 Earnings Call Transcript
Thomas Guslatin: Hello, everyone. This is Thomas Guslatin from the Sanofi IR team. Welcome to the Q1 2025 Conference Call for investors and analysts. As usual, you can find the slides on sanofi.com.
8 Best Gene-Editing Stocks to Buy
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat or prevent diseases.
Billionaire Hedge Funds
